(Reuters) - Ariad Pharmaceuticals Inc said it would discontinue a late-stage trial of its blood cancer drug, barely two weeks after the U.S. Food and Drug Administration placed a partial hold on enrollment for all trials testing the drug.
The company said it had come to an agreement with the FDA that the trial should be terminated as patients treated with the drug, Iclusig, had developed blood clots in their arteries.
(Reporting By Vrinda Manocha in Bangalore; Editing by Rodney Joyce)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp